No Carolina / NY / Florida
Ph: 561.316.3330

Leading Pharma Adopts Veeva Vault Validation Management for Digital Validation Execution and Improved Efficiency

SK Life Science, Inc. uses modern cloud solution to accelerate validation processes for increased inspection readiness

Summation

  • , an innovative pharmaceutical company committed to accelerating the development of next-generation treatments for central nervous system (CNS) disorders and cancer care, adopted Vault Validation Management to further support its team with digital collaboration, standardized processes and workflows, and simpler test execution.
  • , a global biotech company, is using Veeva Vault Validation Management to streamline and accelerate their validation process.
  • The company is building off its success with Veeva Vault QualityDocs and Veeva Vault QMS to optimize its validation programs, driving greater compliance and traceability across all systems.

Veeva Vault Validation Management

Veeva Systems (NYSE: VEEV) today announced that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd., a global biotech company, is using Veeva Vault Validation Management to streamline and accelerate their validation process. By adopting a validation solution with built-in best practices, the company can execute digital validation while centralizing data and improving visibility.

Nina Ricciardelli, director, Veeva Vault Validation Management Comments:

“As the industry continues to shift from traditional paper-based validation, more companies are advancing validation with Veeva Vault Validation Management to streamline and standardize processes. SK Life Science, Inc. is a prime example of one of those forward-thinking companies modernizing validation for greater efficiency and speed.”

SK Life Science

SK Life Science, Inc., an innovative pharmaceutical company committed to accelerating the development of next-generation treatments for central nervous system (CNS) disorders and cancer care, adopted Vault Validation Management to further support its team with digital collaboration, standardized processes and workflows, and simpler test execution. The company is building off its success with Veeva Vault QualityDocs and Veeva Vault QMS to optimize its validation programs, driving greater compliance and traceability across all systems. Shifting to a digital approach provides the transparency necessary to identify trends and proactively address potential issues, reducing compliance risks.

Simplification, Cost Effective

“Veeva Vault Validation Management allows us to further simplify our validation process for significant cost and time-savings in test execution,” said Hina Patel, vice president and global head of quality assurance, SK Life Science, Inc. “Using an advanced validation solution helps improve our efficiency, data integrity, and audit readiness.”

More News

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy